uniQure (NASDAQ:QURE) Shares Gap Up Following Analyst Upgrade

uniQure N.V. (NASDAQ:QURE) gapped up prior to trading on Wednesday after Royal Bank Of Canada raised their price target on the stock from $35.00 to $65.00. The stock had previously closed at $26.99, but opened at $43.55. Royal Bank Of Canada currently has an outperform rating on the stock. uniQure shares last traded at $47.4490, with a volume of 6,117,597 shares.

Several other research analysts have also recently weighed in on QURE. Cantor Fitzgerald raised uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 price objective on the stock in a research report on Wednesday. Leerink Partners raised their target price on uniQure from $36.00 to $70.00 and gave the company an “outperform” rating in a research report on Thursday. TD Cowen restated a “buy” rating on shares of uniQure in a research report on Tuesday, March 3rd. Wall Street Zen upgraded shares of uniQure from a “sell” rating to a “hold” rating in a report on Saturday, March 28th. Finally, Mizuho upgraded shares of uniQure from a “neutral” rating to an “outperform” rating and boosted their target price for the company from $12.00 to $35.00 in a research note on Wednesday, March 11th. Twelve investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, uniQure presently has an average rating of “Moderate Buy” and an average price target of $58.92.

Insider Transactions at uniQure

In related news, Director Rachelle Suzanne Jacques sold 1,993 shares of the company’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $27.06, for a total transaction of $53,930.58. Following the sale, the director owned 33,903 shares of the company’s stock, valued at approximately $917,415.18. This represents a 5.55% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Jeannette Potts sold 5,237 shares of the stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $27.67, for a total transaction of $144,907.79. Following the completion of the sale, the insider owned 133,246 shares in the company, valued at $3,686,916.82. This represents a 3.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 101,054 shares of company stock valued at $2,655,791. Company insiders own 4.65% of the company’s stock.

More uniQure News

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: FDA feedback now suggests uniQure can move ahead with a BLA submission for AMT-130 using existing mid-stage data, significantly improving the regulatory timeline. Reuters
• Positive Sentiment: Cantor Fitzgerald upgraded uniQure to Overweight and raised its price target, reflecting improved confidence in the company’s Huntington’s program. Seeking Alpha
• Positive Sentiment: Barclays also upgraded the stock and lifted its target, adding to the wave of bullish analyst sentiment after the FDA development. Benzinga
• Neutral Sentiment: There were insider sales disclosed this week, including transactions by directors and executives, but these appear to be routine filings and are being overshadowed by the FDA-driven rally.

Institutional Investors Weigh In On uniQure

A number of institutional investors and hedge funds have recently made changes to their positions in QURE. Vanguard Group Inc. increased its position in shares of uniQure by 15.7% in the third quarter. Vanguard Group Inc. now owns 1,125,108 shares of the biotechnology company’s stock worth $65,673,000 after purchasing an additional 152,417 shares during the last quarter. Aberdeen Group plc lifted its position in uniQure by 25.1% during the fourth quarter. Aberdeen Group plc now owns 3,678,640 shares of the biotechnology company’s stock valued at $88,030,000 after purchasing an additional 738,897 shares during the last quarter. Quinn Opportunity Partners LLC bought a new stake in uniQure during the third quarter valued at approximately $6,281,000. Farallon Capital Management LLC grew its stake in uniQure by 3,935.7% in the 3rd quarter. Farallon Capital Management LLC now owns 565,000 shares of the biotechnology company’s stock worth $32,979,000 after buying an additional 551,000 shares in the last quarter. Finally, Boone Capital Management LLC purchased a new position in uniQure in the 3rd quarter worth approximately $8,599,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

uniQure Stock Down 3.9%

The stock’s fifty day moving average price is $24.13 and its 200 day moving average price is $22.03. The stock has a market cap of $2.92 billion, a P/E ratio of -13.30 and a beta of 0.98. The company has a current ratio of 10.40, a quick ratio of 10.40 and a debt-to-equity ratio of 0.33.

uniQure (NASDAQ:QURE) last posted its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The company had revenue of $3.56 million during the quarter, compared to the consensus estimate of $5.21 million. As a group, research analysts forecast that uniQure N.V. will post -3.64 earnings per share for the current fiscal year.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.